STAMFORD, Conn., Oct. 26 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced today that the Company’s management will present at the 2006 C.E. Unterberg, Towbin Life Sciences Conference on October 31, 2006, at The Palace Hotel in New York.
M.S. Koly, Delcath’s President and Chief Executive Officer, is scheduled to present at 1:00 p.m. on October 31st. During his presentation, Mr. Koly will provide an overview of the Company’s ongoing Phase II multi-histology and Phase III Melphalan and Doxorubicin clinical trials for the treatment of advanced stage liver cancer.
A live audio webcast of the presentation will be available for those unable to attend the conference and can be accessed by visiting the Company’s website, http://www.delcath.com. A replay of the presentation will also be available on the site for 90 days following the presentation.
About Delcath Systems, Inc.
Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company’s intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company’s website, http://www.delcath.com.
This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact: Investor Contacts: Delcath Systems, Inc. Todd Fromer / Garth Russell M. S. Koly, Chief Executive Officer KCSA Worldwide 203-323-8668 (212) 896-1215 / (212) 896-1250 www.delcath.comtfromer@kcsa.com / grussell@kcsa.com Media Contacts: Lewis Goldberg KCSA Worldwide (212) 896-1216 lgoldberg@kcsa.com
Delcath Systems, Inc.
CONTACT: M. S. Koly, Chief Executive Officer of Delcath Systems, Inc.,+1-203-323-8668; or Investor, Todd Fromer, +1-212-896-1215,tfromer@kcsa.com, or Garth Russell, +1-212-896-1250, grussell@kcsa.com; orMedia, Lewis Goldberg, +1-212-896-1216, lgoldberg@kcsa.com, all of KCSAWorldwide, for Delcath Systems, Inc.
Web site: http://www.delcath.com/
